^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
EIK1001
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Eikon Therap, Seven and Eight BioPharma
Drug class:
TLR8 agonist, TLR7 agonist, TLR agonist
Related drugs:
Phase 1
Eikon Therapeutics
Active, not recruiting
Last update posted :
04/22/2024
Initiation :
11/21/2019
Primary completion :
07/01/2024
Completion :
07/01/2024
CTLA4 • IL2 • TNFRSF9
|
Tecentriq (atezolizumab) • EIK1001
Share
